¹û¶³Ó°Ôº

¹û¶³Ó°Ôº Business and AGA Nanotech Ltd have concluded a licensing agreement for use of TIPS microparticle technology in directing the controlled delivery of antimicrobial agents in the healthcare setting. The licensing agreement represents the conclusion of a collaborative translational research program supported by the ¹û¶³Ó°Ôº Translational Research Office, ¹û¶³Ó°Ôº Hospitals Biomedical Research Centre, and AGA Nanotech Ltd.

The technology was developed by Dr Richard DayÌý(¹û¶³Ó°Ôº Division of Medicine, Research Department of Metabolism and Experimental Therapeutics) and was one of the ¹û¶³Ó°Ôº translational research projects located in the laboratories at the Stevenage Bioscience Catalyst.Ìý

Dr Day commented: 'TIPS particle technology is an enabling platform with a variety of applications and our relationship withÌýAGA Nanotech LtdÌýÌýrepresents one of our first successful moves into product development. We continue to work with a number of interested parties across a number of application areas where the TIPS particle technology adds sustained and valuable benefits.'

Adrian Fellows (R&D Director, AGA Nanotech Ltd) added: 'The collaboration with Dr Day's group has been highly productive, enabling the testing of ideas that will open up new business opportunities. Aga believes that combining the TIPS delivery system with our own distinct antimicrobial expertise offers unique opportunities to replace conventional antibiotics, not only in healthcare and woundcare, but also in animal health and welfare.'

Professor Bryan Williams (¹û¶³Ó°Ôº Hospitals Biomedical Research Centre (BRC) Director), said: "I am delighted that the BRC's support and experience in bringing medical innovations to our patients has helped facilitate this exciting development; and look forward to seeing the TIPS microparticle technology in our clinical practice."

The agreement was negotiated on behalf of the ¹û¶³Ó°Ôº by its technology commercialisation office, ¹û¶³Ó°Ôº Business. Cengiz Tarhan, Managing Director of ¹û¶³Ó°Ôº Business commented: 'TIPS has wide applicability and the development of a partnership between AGA Nanotech LtdÌýand ¹û¶³Ó°Ôº in this breakthrough area has been highly productive. The signing of this agreement represents a significant milestone and is a pivotal step in the progression of the TIPS particle technology into marketed products which support healthcare as they tackle the challenge of antimicrobial resistance.'

Links

¹û¶³Ó°Ôº Translational Research Office